Skip to main content
Premium Trial:

Request an Annual Quote

Arbitration Panel Rules Operon Must Pay Qiagen $2.1M

NEW YORK (GenomeWeb News) – Operon Biotechnologies must pay Qiagen $2.1 million as a result of an arbitration panel ruling, Qiagen disclosed in a regulatory filing.

In its quarterly earning document filed with the US Securities and Exchange Commission earlier this month, Qiagen said that the arbitration panel ruled in its favor in a supply agreement dispute between the two companies.

In 2009, Operon began arbitration proceedings against Qiagen, claiming Qiagen failed to comply with the preferred supplier provisions of their agreement, resulting in lost profits and other damages. Qiagen disputed the allegations and asserted counterclaims, and in June the arbitration panel ruled in favor of Qiagen on all claims, Qiagen said.

Operon is now Eurofins MWG Operon, based in Ebersberg, Germany, and offers custom oligos, and oligos and sequencing services.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.